Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2008
11/20/2008WO2008116195A3 Compositions comprising an sglt2 ingibitor for treating obesity
11/20/2008WO2008116053A3 Fap-activated chemotherapeutic compounds, and methods of use thereof
11/20/2008WO2008115470A3 Hox-gene expression as a biomarker for igf-1r therapeutics
11/20/2008WO2008114017A3 Compositions and methods relating to influenza infection
11/20/2008WO2008113851A3 Novel c11 modified retrosteroids as progesterone receptor modulator compounds
11/20/2008WO2008113559A3 Indolizines and aza-analog derivatives thereof as cns active compounds
11/20/2008WO2008112715A3 Novel agents of calcium ion channel modulators
11/20/2008WO2008112659A3 Regulation of osteopontin
11/20/2008WO2008112368A3 Phenylalkylcarboxylic acid delivery agents
11/20/2008WO2008112278A3 Methods and compositions for modulating insulin secretion and glucose metabolism
11/20/2008WO2008109697A3 Ppar active compounds
11/20/2008WO2008109551B1 Nucleic acid compounds for inhibiting tacstd1 gene expression and uses thereof
11/20/2008WO2008109544B1 Nucleic acid compounds for inhibiting muc1 gene expression and uses thereof
11/20/2008WO2008109534B1 Nucleic acid compounds for inhibiting ezh2 gene expression and uses thereof
11/20/2008WO2008109492B1 Nucleic acid compounds for inhibiting igf1r gene expression and uses thereof
11/20/2008WO2008109472A3 Nucleic acid compounds for inhibiting pcsk9 gene exprression and uses thereof
11/20/2008WO2008109450A3 Nucleic acid compounds for inhibiting id-1 gene expression and uses thereof
11/20/2008WO2008109382B1 Nucleic acid compounds for inhibiting pkn3 gene expression and uses thereof
11/20/2008WO2008109379B1 Nucleic acid compounds for inhibiting il17a gene expression and uses thereof
11/20/2008WO2008109376B1 Nucleic acid compounds for inhibiting bcr-abl gene expression and uses thereof
11/20/2008WO2008109356B1 Nucleic acid compounds for inhibiting tnfsf13b gene expression and uses thereof
11/20/2008WO2008106226A3 Macrolide compounds and methods of making and using the same
11/20/2008WO2008104880A3 Stable solid dosage forms of an antidepressant
11/20/2008WO2008103707A8 Mono-and di-phosphates of 3-(3-fluoro-4-hydroxy-phenyl)-7-hydroxy-naphthalene-1-carbonitrile
11/20/2008WO2008103139A3 Shea butter dimethicone copolyols
11/20/2008WO2008101214A3 Fixed drug ratios for treatment of hematopoietic cancers and proliferative disorders
11/20/2008WO2008101147A3 Methods and compositions for regulating bone mineral density
11/20/2008WO2008101084A3 Methods and compositions for the disruption of biofilms
11/20/2008WO2008101052A8 Compositions and methods for treating, reducing, ameliorating, or preventing infections of the ear or upper respiratory tract
11/20/2008WO2008100562A3 Indoleamine 2,3-dioxygenase, pd-1/pd-l pathways, and ctla4 pathways in the activation of regulatory t cells
11/20/2008WO2008097924A3 Pharmaceutical compositions comprising dextromethorphan analogs for the treatment of neurological disorders
11/20/2008WO2008097897A9 Pharmaceutical compositions containing substituted indole acid derivatives as inhibitors of plasminogen activator inhibitor-1(pai-1)
11/20/2008WO2008097504A3 Use of a trpm5 inhibitor to regulate insulin and glp-1 release
11/20/2008WO2008097459A3 Dual-acting antihypertensive agents
11/20/2008WO2008096203A3 Food extracts containing n-methylnicotinamide for treatment of lipoprotein abnormalities and skin diseases and disorders
11/20/2008WO2008095479A3 Use of a highly emulsified silicone oil (hes) for the production of a medicament
11/20/2008WO2008094912B1 Substituted gamma lactams as therapeutic agents
11/20/2008WO2008092591A3 Use of guanidinoacetic acid (salts) combined with betaine and/or choline for producing a health-promoting agent
11/20/2008WO2008092099A3 Compositions and methods for treating hematopoietic malignancies
11/20/2008WO2008091740A3 Polyelectrolyte precipitation and purification of antibodies
11/20/2008WO2008089126A3 Cd45 and methods and compounds related thereto
11/20/2008WO2008082885A3 Transport molecules using reverse sequence hiv-tat polypeptides
11/20/2008WO2008080092A3 Compositions comprising bile acid sequestrants for treating esophageal disorders
11/20/2008WO2008070313A3 3-(dihydro-1h-pyrazolo [4,3-d] pyrimidin-5-yl)-4-propoxybenzenesulfonamide derivatives and methods of use
11/20/2008WO2008070082A3 Stem-progenitor cell specific micro-ribonucleic acids and uses thereof
11/20/2008WO2008066576A3 Methods for screening antimicrobial and antiviral compounds and uses thereof
11/20/2008WO2008065408A3 Modulation of prostaglandin/cyclooxygenase metabolic pathways
11/20/2008WO2008064351A3 (r)-n-stereoisomers of 7,8-saturated-4,5-epoxy-morphinanium analogs
11/20/2008WO2008063318A3 Betulinic acid, derivatives and analogs thereof and uses therefor
11/20/2008WO2008063211A3 Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
11/20/2008WO2008062453B1 Composition containing nicotine base aromatic oils and alkyl salicylate for the delivery of nicotine base in vapour form
11/20/2008WO2008062450A3 Crystalline polymorphs of ciclesonide
11/20/2008WO2008058993A3 Use of alpha ketogluaric acid for the treatment of infection with h. pylori
11/20/2008WO2008057171A3 4-1 bb ligand in inflammatory diseases
11/20/2008WO2008054599A3 Rho kinase inhibitors
11/20/2008WO2008051475A3 Hcv ns3 protease inhibitors
11/20/2008WO2008048976A3 Enhancing disease resistance against rna viral infections with intracytoplasmic pathogen sensors
11/20/2008WO2008045641A3 Composition s comprising a benzodiazepine, an alcohol aversive agent and an abuse aversive agent
11/20/2008WO2008033894A3 Compounds with activity at estrogen receptors
11/20/2008WO2008033417A3 Methods and compositions for sealing and adhering biological tissues and medical uses thereof
11/20/2008WO2008033299A3 Use of n-containing spirocompounds for the enhancement of cognitive function
11/20/2008WO2008031817A3 Histone deacetylase inhibitors with combined activity on class-i and class-iib histone deacetylases in combination with proteasome inhibitors
11/20/2008WO2008030412A3 Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease
11/20/2008WO2008030390A3 Ophthalmic compositions for treating ocular hypertension
11/20/2008WO2008028060B1 Anti-tumor compounds for inhibiting cancer growth
11/20/2008WO2008027812A3 Imidazopyridine and imidazopyrimidine derivatives
11/20/2008WO2008024660A3 Method of reducing neuronal cell damage
11/20/2008WO2008024435A3 Dendritic molecular intracellular transporters and methods of making and using same
11/20/2008WO2008024423A3 4-thio substituted quinoline and naphthyridine compounds
11/20/2008WO2008024355A3 Suppression of estrus in mares by a single injection method
11/20/2008WO2008024284A3 Sulfonylated piperazines as cannabinoid-1 receptor modulators
11/20/2008WO2008022309A3 Polyconjugates for in vivo delivery of polynucleotides
11/20/2008WO2008022128A3 Transdermal delivery of meptazinol
11/20/2008WO2008021970A3 Treatment of motor neuron disease, including certain neurological disorders, motor neuropathies and chronic inflammatory diseases
11/20/2008WO2008021439A3 Compositions and methods for treatment of cardiac hypertrophy
11/20/2008WO2008019395A3 Compounds for improving learning and memory
11/20/2008WO2008016475A3 Immune response modifier compositions and methods
11/20/2008WO2008014510A3 Crystalline form a of ibandronic acid and process for the preparation
11/20/2008WO2008014221A3 Bridged carbamate macrolides
11/20/2008WO2008013985A3 Use of heat shock activators for tissue regeneration
11/20/2008WO2008013966A3 Use of 8-quinolinol and its analogs to target cancer stem cells
11/20/2008WO2008008852A3 Cxcr4 antagonists including heteroatoms for the treatment of medical disorders
11/20/2008WO2008006052A3 Bicyclic heteroaryl inhibitors of pde4
11/20/2008WO2007147404A3 Pharmaceutical composition with an extracellular polyanion from arthrospira
11/20/2008WO2007147134A3 Treating obesity with muscarinic receptor m1 antagonists
11/20/2008WO2007138041A8 Novel 1,4-diaza-bicyclo[3.2.2]nonyl pyrimidinyl derivative and its medical use
11/20/2008WO2007138040A8 Novel 1,4-diaza-bicyclo[3.2.2]nonyl pyrimidinyl derivative and its medical use
11/20/2008WO2007133772A3 Cdki pathway inhibitors as selective inhibitors of tumor cell growth
11/20/2008WO2007131168A3 Inhibitors of secretion of hepatitis b virus antigens for treatment of a chronic hepatitis virus
11/20/2008WO2007129019A8 Sulfonamide compounds useful as edg receptor modulators
11/20/2008WO2007124171A3 Compositions and methods for treating trinucleotide repeat disorders
11/20/2008WO2007120605A3 Treatment for nicotine-induced lung disease using peroxisome proliferator-activated receptor gamma agonists
11/20/2008WO2007118227A3 Naphthalenedione compounds
11/20/2008WO2007110418A3 Substituted 5-hetaryl-4-aminopyrimidines
11/20/2008WO2007109661A3 Methods of preparation and resolution of e/z isomers of vinylfuro[2,3-d] pyrimidine and their biological activities
11/20/2008WO2007109362A3 Benzoimidazolyl-parazine compounds for inflammation and immune-related uses
11/20/2008WO2007106792A3 Methods for treating sarcopenia with a growth hormone secretagogue
11/20/2008WO2007106400A3 Pyridine-containing macroheterocylic compounds as kinase inhibitors
11/20/2008WO2007103557A3 Coating capsules with active pharmaceutical ingredients
11/20/2008WO2007102883A3 Chemical compounds
1 ... 2985 2986 2987 2988 2989 2990 2991 2992 2993 2994 2995 2996 2997 2998 2999 3000 3001 3002 3003 3004 3005 ... 7860